Pertussis Vaccine (Tdap) Recommended for Pregnant Women
recently published "Updated Recommendations for Use of Tdap Vaccine in
Since 2005, the Advisory Committee on Immunization Practices (ACIP)
has recommended tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis (Tdap) booster
vaccines to unvaccinated postpartum mothers and other family members of
newborn infants to protect infants from pertussis, a strategy referred to as
cocooning. On June 22, 2011, ACIP made recommendations for use of Tdap in
unvaccinated pregnant women and updated recommendations on cocooning and special
The Advisory Committee on Immunization Practices (ACIP) recommends:
A single Tdap dose for persons aged 11 through 18 years who have
completed the recommended childhood diphtheria and tetanus toxoids and
pertussis/diphtheria and tetanus toxoids and acellular pertussis (DTP/DTaP)
vaccination series, and
For adults aged 19 through 64 years who have not previously received
ACIP also recommends that adults aged 65 years and older receive a
single dose of Tdap if they have or anticipate having close contact with an
infant aged <12 months and previously have not received Tdap.
Two Tdap vaccines are available in the United States. Adacel (Sanofi
Pasteur) is licensed for use in persons aged 11 through 64 years. Boostrix
(GlaxoSmithKline Biological) is licensed for use in persons aged ≥10 years.
Recommendation for Tetanus, Diphtheria and Pertussis (Tdap) Vaccine During Pregnancy
ACIP recommends that pregnant women who have not been previously
vaccinated with Tdap should get one dose of Tdap during the third trimester
second trimester (after 20 weeks gestation). If not administered during
pregnancy, Tdap should be administered immediately postpartum.
ACIP concluded that available data from the studies did not suggest
any elevated frequency or unusual patterns of adverse events in pregnant
women who received Tdap and that the few serious adverse events reported
were unlikely to have been caused by the vaccine.
When Tdap is administered during pregnancy, at time of
delivery the mother will be protected, making her less likely to
transmit pertussis to her infant and transplacental maternal antibodies will
likely protect the infant against pertussis in early life.
As part of standard wound management care to prevent tetanus, a tetanus
toxoid—containing vaccine might be recommended for wound management in a
pregnant woman if 5 years or more have elapsed since last receiving Td. If a
tetanus booster is indicated for a pregnant woman who previously has not
received Tdap, Tdap should be administered.
Providers are encouraged to report Tdap administrations regardless of
the trimester, to the appropriate manufacturer's pregnancy registry: for
Boostrix® to GlaxoSmithKline Biologicals at 1-888-825-5249, or for Adacel®,
to sanofi pasteur at 800-822-2463. 11
What is Pertussis?
Pertussis is a highly contagious bacterial disease that causes uncontrollable, violent coughing. The coughing can make it hard to breathe. A deep "whooping" sound is often heard when the patient tries to take a breath.
Pertussis, or whooping cough, is an upper respiratory infection caused by the Bordetella pertussis or Bordetella parapertussis bacteria. The coughing can make it hard to breathe. A deep "whooping" sound is often heard when the patient tries to take a breath. It is a serious disease that can cause permanent disability in infants, and even death.
When an infected person sneezes or coughs, tiny droplets containing the bacteria move through the air, and the disease is easily spread from person to person. The infection usually lasts 6 weeks.
To learn more about, Vaccination Guidelines for Pregnant Woman,
Dated 09 December 2011